XML 95 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Balance Sheet Details (Tables)
12 Months Ended
Dec. 31, 2019
Condensed Financial Information Disclosure [Abstract]  
Schedule of Short-term Marketable Securities
Short-term marketable securities, consisting of equity securities and debt securities, were as follows as of the dates indicated:  
 
December 31, 2019
(In millions)
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Market
Value
Debt securities, available for sale:
 
 
 
 
 
 
 
U.S. government agencies
$
675.6

 
$
0.4

 
$

 
$
676.0

Commercial paper
248.1

 
0.1

 

 
248.2

Corporate debt
163.0

 

 
(0.1
)
 
162.9

Total debt securities, available for sale
$
1,086.7

 
$
0.5

 
$
(0.1
)
 
$
1,087.1

 
December 31, 2018
(In millions)
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Market
Value
Equity investment in Tandem Diabetes Care, Inc
$
2.0

 
$
36.0

 
$

 
$
38.0

 
 
 
 
 
 
 
 
Debt securities, available for sale:
 
 
 
 
 
 
 
U.S. government agencies
$
173.2

 
$

 
$
(0.1
)
 
$
173.1

Commercial paper
36.2

 

 

 
36.2

Corporate debt
1.3

 

 

 
1.3

Total debt securities, available for sale
$
210.7

 
$

 
$
(0.1
)
 
$
210.6

 
 
 
 
 
 
 
 
Total marketable securities
$
212.7

 
$
36.0

 
$
(0.1
)
 
$
248.6


Schedule of Reconciliation of Net Gain (Loss) Recognized on Equity Securities
The following table reconciles the net gain recognized on equity securities during the twelve months ended December 31, 2019, 2018 and 2017 to the unrealized gain recognized during those periods on equity securities still held at the reporting dates.
 
Twelve Months Ended 
 December 31,
(In millions)
2019
 
2018
 
2017
Net gains and losses recognized during the period on equity securities
$
(4.2
)
 
$
80.1

 
$

Less: Net gains and losses recognized during the period on equity securities sold during the period
4.2

 
(44.1
)
 

Unrealized gains recognized during the reporting period on equity securities still held at the reporting date
$

 
$
36.0

 
$


Schedule of Accounts Receivable
 
December 31,
(In millions)
2019
 
2018
Accounts receivable
$
292.1

 
$
233.9

Less allowance for doubtful accounts
(5.8
)
 
(7.2
)
Total accounts receivable, net
$
286.3

 
$
226.7


Schedule of Inventory
 
December 31,
(In millions)
2019
 
2018
Raw materials
$
64.9

 
$
30.8

Work-in-process
11.1

 
11.2

Finished goods
43.8

 
28.7

Total inventory
$
119.8

 
$
70.7


Schedule of Property and Equipment
 
December 31,
(In millions)
2019
 
2018
Building and land
$
15.5

 
$
6.0

Furniture and fixtures
12.8

 
9.0

Computer software and hardware
32.7

 
29.2

Machinery and equipment
130.2

 
80.7

Leasehold improvements
102.5

 
80.7

Construction in progress
132.6

 
57.3

Total cost
426.3

 
262.9

Less accumulated depreciation and amortization
(105.0
)
 
(79.8
)
Total property and equipment, net
$
321.3

 
$
183.1


Schedule of Accounts Payable and Accrued Liabilities
 
December 31,
(In millions)
2019
 
2018
Accounts payable trade
$
102.3

 
$
75.5

Accrued tax, audit, and legal fees
14.0

 
11.7

Accrued rebates
93.3

 
36.1

Accrued warranty
7.4

 
6.8

Other accrued liabilities
39.4

 
17.0

Total accounts payable and accrued liabilities
$
256.4

 
$
147.1


Schedule of Accrued Warranty Reconciliations of our accrued warranty costs for the twelve months ended December 31, 2019 and 2018 were as follows:
 
Twelve Months Ended
December 31,
(In millions)
2019
 
2018
Beginning balance
$
6.8

 
$
8.8

Charges to costs and expenses
32.7

 
17.4

Costs incurred
(32.1
)
 
(19.4
)
Ending balance
$
7.4

 
$
6.8


Schedule of Other Long-Term Liabilities
 
December 31,
(In millions)
2019
 
2018
Finance lease obligations
$
14.4

 
$
7.3

Deferred rent

 
9.4

Other liabilities
5.7

 
3.3

Total other liabilities
$
20.1

 
$
20.0